AC Immune (NASDAQ:ACIU - Get Free Report)'s share price was down 3.9% on Monday . The stock traded as low as $1.94 and last traded at $1.99. Approximately 150,325 shares were traded during mid-day trading, an increase of 4% from the average daily volume of 145,007 shares. The stock had previously closed at $2.07.
Wall Street Analyst Weigh In
Several analysts have weighed in on ACIU shares. Wall Street Zen upgraded shares of AC Immune from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th. HC Wainwright decreased their target price on shares of AC Immune from $16.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, May 1st.
Check Out Our Latest Stock Analysis on AC Immune
AC Immune Stock Performance
The stock has a market capitalization of $211.87 million, a P/E ratio of -3.64 and a beta of 1.62. The firm's fifty day simple moving average is $1.85 and its 200 day simple moving average is $2.14.
AC Immune (NASDAQ:ACIU - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. AC Immune had a negative net margin of 177.79% and a negative return on equity of 44.60%. The firm had revenue of $1.12 million for the quarter, compared to analyst estimates of $1.99 million. Analysts anticipate that AC Immune will post -0.62 earnings per share for the current fiscal year.
Institutional Investors Weigh In On AC Immune
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quinn Opportunity Partners LLC bought a new stake in shares of AC Immune during the 4th quarter valued at approximately $27,000. Two Sigma Advisers LP bought a new stake in shares of AC Immune during the 4th quarter valued at approximately $36,000. Boothbay Fund Management LLC bought a new stake in shares of AC Immune during the 4th quarter valued at approximately $38,000. Banque Cantonale Vaudoise bought a new stake in shares of AC Immune during the 1st quarter valued at approximately $50,000. Finally, RPO LLC bought a new stake in shares of AC Immune during the 4th quarter valued at approximately $51,000. 51.36% of the stock is owned by institutional investors.
AC Immune Company Profile
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
See Also
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
